儿童肥胖相关心肌病的分子机制

牛婉侠; 梁爽; 王一彪

doi:10.11852/zgetbjzz2022-0978

PDF(591 KB)

中国儿童保健杂志 ›› 2023, Vol. 31 ›› Issue (5) : 507-511. DOI: 10.11852/zgetbjzz2022-0978

综述

儿童肥胖相关心肌病的分子机制

牛婉侠, 梁爽, 王一彪

作者信息 +

Molecular mechanism of childhood obesity related cardiomyopathy

NIU Wanxia, LIANG Shuang, WANG Yibiao

Author information +

文章历史 +

摘要

肥胖并发症随着肥胖发病率的不断增长呈现逐年上升趋势。研究表明,心血管疾病的风险增加与肥胖密切相关:冠状动脉粥状硬化、心力衰竭和心律失常。同时肥胖也与心肌肥厚、心室收缩功能障碍和舒张顺应性降低等发生发展有关。单纯性肥胖儿童心脏舒张功能较正常体重儿童明显降低,肥胖导致心肌病的病理机制有多种,包括胰岛素抵抗、炎症、氧化应激、脂肪毒性、调亡和线粒体自噬等。肥胖导致心脏结构和功能发生变化的精确分子机制仍不清楚。本文就肥胖所致心肌重构的可能分子机制做一简要综述,为临床上儿童肥胖相关心肌病的防治提供理论依据。

Abstract

Childhood obesity complications are increasing year by year with the continuous growth of obesity incidence rate.Studies have shown that the increased risk of cardiovascular disease (coronary atherosclerosis, heart failure and arrhythmia) is closely related to obesity.Additionally, obesity is also related to the occurrence and development of myocardial hypertrophy, ventricular systolic dysfunction and reduced diastolic compliance.The diastolic function of simple obese children is significantly lower than that of normal weight children.There are many pathological mechanisms of cardiomyopathy caused by obesity, including insulin resistance, inflammation, oxidative stress, lipotoxicity, apoptosis and mitochondrial autophagy.However, the precise molecular mechanism by which obesity leads to changes in cardiac structure and function remains unclear.This article briefly reviews the possible molecular mechanisms of obesity-induced myocardial remodeling, and provides theoretical basis for the prevention and treatment of obesity related cardiomyopathy in children.

导出引用

牛婉侠, 梁爽, 王一彪. 儿童肥胖相关心肌病的分子机制[J]. 中国儿童保健杂志. 2023, 31(5): 507-511 https://doi.org/10.11852/zgetbjzz2022-0978

NIU Wanxia, LIANG Shuang, WANG Yibiao. Molecular mechanism of childhood obesity related cardiomyopathy[J]. Chinese Journal of Child Health Care. 2023, 31(5): 507-511 https://doi.org/10.11852/zgetbjzz2022-0978

中图分类号： R723.14

参考文献

[1] Zeng Q, Li N, Pan XF, et al.Clinical management and treatment of obesity in China[J].Lancet Diabetes Endo, 2021, 9(6): 393-405.
[2] 何耀.我国超重/肥胖流行趋势及其对公共卫生的挑战[J].中华流行病学杂志, 2014, 35(4): 4.
He Y.The epidemic trend of over weight/obesity in China and its challenge to public health[J].Chin J Epidemio, 2014, 35 (4): 4.(in Chinese)
[3] 国务院新闻办公室.《中国居民营养与慢性病状况报告(2020年)》国务院新闻办公室2020年12月23日新闻发布会(摘要)[J].营养学报,2020,42(6):521.
Information Office of the State Council.Report on nutrition and chronic diseases of Chinese residents (2020) press conference (abstract) of the state council information office on December 23, 2020[J].Journel of Nutrition,2020,42(6):521.(in Chinese)
[4] Chung A, Backholer K, Wong E, et al.Trends in child and adolescent obesity prevalence in economically advanced countries according to socioeconomic position: A systematic review[J].Obes Rev, 2016, 17(3): 276-295.
[5] NCD Risk Factor Collaboration(NCD-Risc)Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016:A pooled analysis of 2 416 population-based measurement studies in 128.9 million children, adolescents, and adults[J].Lancet, 2017, 390(10113): 2627-2642.
[6] Dejong KA, Czeczor JK, Sithara S, et al.Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study[J].Cardiovasc Diabetol, 2017, 16(1): 21.
[7] 李梅, 张晓蓉, 薛爱玲.超声心动图检测单纯性肥胖儿童心脏功能的改变[J].中国临床医生杂志, 2014,43(7):3.
Li M, Zhang XR, Xue AL.Detection of cardiac function changes in simple obese children by echocardiography[J].Chin J Clin, 2014,43(7):3.(in Chinese)
[8] Jing L, Nevius CD, Friday CM, et al.Ambulatory systolic blood pressure and obesity are independently associated with left ventricular hypertrophic remodeling in children[J].J Cardiovasc Magn Reson, 2017, 19(1): 86.
[9] Heiser D, Rubert J, Unterreiner A, et al.Evaluation of protein kinase D auto-phosphorylation as biomarker for NLRP3 inflammasome activation[J].PLoS One, 2021, 16(11): e0248668.
[10] Renton MC, Mcgee SL, Howlett KF.The role of protein kinase D (PKD) in intracellular nutrient sensing and regulation of adaptive responses to the obese environment[J].Obes Rev, 2021, 22(3): e13145.
[11] Lv D, Chen H, Feng Y, et al.Small-molecule inhibitor targeting protein kinase D:A potential therapeutic strategy[J].Front Oncol, 2021, 11: 680221.
[12] Steinberg SF.Decoding the cardiac actions of protein kinase D isoforms[J].Mol Pharmacol, 2021, 100(6): 558-567.
[13] Venardos K, Dejong KA, Elkamie M, et al.The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice[J].PLoS One, 2015, 10(3): e0120934.
[14] Liu X, Xu Q, Wang X, et al.Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model[J].Pharmacol Res, 2015, 93: 43-51.
[15] Indoliya A, Pal K, Pattnaik AK, Poddar R.In vivo morphological study of obese development in mice model guided by swept-source optical coherence tomography (SSOCT).[J]. Biotech,2022,12(11):282.
[16] Jong K, Hall LG, Renton MC, et al.Loss of protein kinase D activity demonstrates redundancy in cardiac glucose metabolism and preserves cardiac function in obesity[J].Mol Metab, 2020, 42: 101-105.
[17] Zhang Y, Whaley-connell AT, Sowers JR, et al.Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management[J].Pharmacol Ther, 2018, 191: 1-22.
[18] Zhang Y, Sowers JR, Ren J.Targeting autophagy in obesity:From pathophysiology to management[J].Nat Rev Endocrinol, 2018, 14(6): 356-376.
[19] Virani SS, Alonso A, Benjamin EJ, et al.Heart disease and stroke statistics-2020 update:A report from the American heart association[J].Circulation, 2020, 141(9): e139-e596.
[20] Tong M, Saito T, Zhai P, et al.Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy[J].Circ Res, 2019, 124(9): 1360-1371.
[21] An M, Dong-Ryeol R, Jang WP, et al.ULK1 prevents cardiac dysfunction in obesity through autophagy-meditated regulation of lipid metabolism[J].Cardiovasc Res, 2017, 113(10): 1137.
[22] Li G, Li J, Shao R, et al.FUNDC1: A promising mitophagy regulator at the mitochondria-associated membrane for cardiovascular diseases[J].Front Cell Dev Biol, 2021, 9: 788634.
[23] Ren J, Sun M, Zhou H, et al.FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity[J].Sci Adv, 2020, 6(38):eabc8561.
[24] Czech MP.Insulin action and resistance in obesity and type 2 diabetes[J].Nat Med, 2017, 23(7): 804-814.
[25] Chen F, Liu J, Hou D, et al.The relationship between fat mass percentage and glucose metabolism in children and adolescents: A systematic review and meta-analysis[J].Nutrients,2022,14(11):2272.
[26] Munoz MC, Piazza VG, Burghi V, et al.Insulin signaling in the heart is impaired by growth hormone: A direct and early event[J].J Mol Endocrinol, 2022, 69(2): 357-376.
[27] Lee J, Vijayakumar A, White PJ, et al.BCAA supplementation in mice with diet-induced obesity alters the metabolome without impairing glucose homeostasis[J].Endocrinology, 2021,162(7):bqab062.
[28] Wang W, Zhang F, Xia Y, et al.Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction[J].Am J Physiol Heart Circ Physiol, 2016, 311(5): H1160-h9.
[29] Kroemer G, Loper-Otin C, Madeo F, et al.Carbotoxicity-noxious effects of carbohydrates[J].Cell, 2018, 175(3): 605-614.
[30] Mcnay EC, Pearson-leary J.GluT4: a central player in hippocampal memory and brain insulin resistance[J].Exp Neurol, 2020, 323: 113076.
[31] Bertrand L, Auquier J, Renguet E, et al.Glucose transporters in cardiovascular system in health and disease[J].Pflugers Arch, 2020, 472(9): 1385-1399.
[32] Seidelmann SB, Feofanova BE, Yu CB, et al.Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk[J].J Am Coll of Cardiol, 2018, 72(15): 1763-1773.
[33] Rayner JJ, Banerjee R, Holloway CJ, et al.Correction: the relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity[J].Int J Obes (Lond), 2019, 43(8): 1652.
[34] Zhang L, Ussher JR, Oka T, et al.Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation[J].Cardiovasc Res, 2011, 89(1): 148-156.
[35] Nakamura M, Liu T, Husain S, et al.Glycogen synthase kinase-3α promotes fatty acid uptake and lipotoxic cardiomyopathy[J].Cell Metab, 2019, 29(5): 1119-1134,e12.
[36] Costantino S, Akhmedov A, Melina G, et al.Obesity-induced activation of Jund promotes myocardial lipid accumulation and metabolic cardiomyopathy[J].Eur Heart J, 2019, 40(12): 997-1008.
[37] Rossi A, Pizzo P, Filadi R.Calcium, mitochondria and cell metabolism: A functional triangle in bioenergetics[J].Biochim Biophys Acta Mol Cell Res, 2019, 1866(7): 1068-1078.
[38] Xu HX, Cui SM, Zhang YM, et al.Mitochondrial Ca(2⁺) regulation in the etiology of heart failure: Physiological and pathophysiological implications[J].Acta Pharmacol Sin, 2020, 41(10): 1301-1309.
[39] Goodman JB, Qin F, Morgan RJ, et al.Redox-resistant SERCA [sarco(endo)plasmic reticulum calcium ATPase] attenuates oxidant-stimulated mitochondrial calcium and apoptosis in cardiac myocytes and pressure overload-induced myocardial failure in mice[J].Circulation, 2020, 142(25): 2459-2569.
[40] Gorski PA, Jang SP, Jeong D, et al.Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca(2+)-ATPase in heart failure[J].Circ Res, 2019, 124(9): e63-e80.
[41] Mazeto FS, Okoshi K, Silveira C, et al.Calcium homeostasis behavior and cardiac function on left ventricular remodeling by pressure overload[J].Braz J Med Biol Res, 2021, 54(4): e10138.
[42] Bartoli F, Bailey MA, Rode B, et al.Orai1 channel inhibition preserves left ventricular systolic function and normal Ca²⁺ handling after pressure overload[J].Circulation, 2020,141(3):199-216.
[43] Hegyi B, Bers DM, Bossuyt J.CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy[J].J Mol Cell Cardiol, 2019, 127: 246-259.
[44] Zhong P, Quan D, Peng J, et al.Corrigendum to “Role of CaMKII in free fatty acid/hyperlipidemia-induced cardiac remodeling both in vitro and in vivo”[J].J Mol Cell Cardiol, 2018, 121: 306.
[45] Ren J, Wu NN, Wang S, et al.Obesity cardiomyopathy: evidence, mechanisms and therapeutic implications[J].Physiol Rev, 2021,101(4):1745-1807.
[46] Thoudam T, Ha CM, Leem J, et al.PDK4 augments ER-Mitochondria contact to dampen skeletal muscle insulin signaling during obesity[J].Diabetes, 2019, 68(3): 571-586.